Skip to main content
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
FR
CDA | Evidence Driven
  • Find Reports
    • Programs & Initiatives
      • Advisory Panel: Pan-Canadian Prescription Drug List
      • Aging in Place
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Emergency Department Overcrowding
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • How to Become Involved
      • Patient Groups
      • Pan-Canadian Collaborative
CDA | Evidence Driven
FR
  • Find Reports
  • Our Work
    • Programs & Initiatives
      • Advisory Panel: Pan-Canadian Prescription Drug List
      • Aging in Place
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Emergency Department Overcrowding
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
  • Get Involved
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • How to Become Involved
      • Patient Groups
      • Pan-Canadian Collaborative
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
Evidence Bundle
Evidence for Medical Imaging

Publicly Funded PET-CT Indications: A Pan-Canadian Comparison

Submitted by [email protected] on Mon, 08/29/2022 - 14:36
  • Read more about Publicly Funded PET-CT Indications: A Pan-Canadian Comparison

Publicly Funded PET-CT Indications: Comparison of Canada With Other Countries

Submitted by [email protected] on Mon, 08/29/2022 - 14:35
  • Read more about Publicly Funded PET-CT Indications: Comparison of Canada With Other Countries

Mobile CT and MRI Units in Canada, 2019-2020

Submitted by [email protected] on Mon, 08/29/2022 - 14:32
  • Read more about Mobile CT and MRI Units in Canada, 2019-2020

Mobile Imaging: The Benefits and Challenges

Submitted by [email protected] on Mon, 08/29/2022 - 14:31
  • Read more about Mobile Imaging: The Benefits and Challenges

The Future of PET-CT in Canada

Submitted by [email protected] on Mon, 08/29/2022 - 14:29
  • Read more about The Future of PET-CT in Canada

The Age of Imaging Equipment in Canada

Submitted by [email protected] on Mon, 08/29/2022 - 14:28
  • Read more about The Age of Imaging Equipment in Canada

The Procurement of Advanced Imaging Equipment: A Pan-Canadian Comparison

Submitted by [email protected] on Mon, 08/29/2022 - 13:58
  • Read more about The Procurement of Advanced Imaging Equipment: A Pan-Canadian Comparison

The Role of Neuroimaging in Drugs Targeting Amyloid-Beta in Alzheimer Disease: Part 1

Submitted by [email protected] on Mon, 08/29/2022 - 14:25
  • Read more about The Role of Neuroimaging in Drugs Targeting Amyloid-Beta in Alzheimer Disease: Part 1

The Role of Neuroimaging in Drugs Targeting Amyloid-Beta in Alzheimer Disease: Part 2

Submitted by [email protected] on Mon, 08/29/2022 - 14:23
  • Read more about The Role of Neuroimaging in Drugs Targeting Amyloid-Beta in Alzheimer Disease: Part 2

The Implementation Considerations of PET-CT

Submitted by [email protected] on Mon, 08/29/2022 - 14:17
  • Read more about The Implementation Considerations of PET-CT

Pagination

  • Page 1
  • Next page ››

Canada’s Drug Agency is a pan-Canadian health organization. Created and funded by Canada’s federal, provincial, and territorial governments, we’re responsible for driving better coordination, alignment, and public value within Canada’s drug and health technology landscape.

  • [email protected]
  • Reports
  • Contact
  • Careers
  • Help

Stay up to date on the latest from Canada’s Drug Agency by subscribing to our newsletter.

Already subscribed? Update your preferences.

  • visit us on facebook
  • visit us on linkedin
  • visit us on twitter
  • visit us on youtube
  • visit us on instagram

© 2024 Canadian Agency for Drugs and Technologies in Health

  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Request for Archived Report
Back to Top